C-Flox 250 (Ciprofloxacin)

ciprofloxacin 250 mg tablet, 14 · ORAL · PBS code 1208N

AUTHORITY_REQUIRED

What it costs

AU$3.48 PBS-determined price per 14 units

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

• First listed on the PBS: 2002-02-01.
• Repeats: 0.
• PBS program: GE.

Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Respiratory tract infection

The condition must be proven or suspected to be caused by Pseudomonas aeruginosa; AND

Patient must be severely immunocompromised.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Bacterial gastroenteritis

Patient must be severely immunocompromised.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Infection

The condition must be proven to be due to Pseudomonas aeruginosa resistant to all other oral antimicrobials; or

The condition must be proven to be due to other gram-negative bacteria resistant to all other oral antimicrobials.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Bone or joint infection

The condition must be suspected or proven to be caused by gram-negative bacteria resistant to all other appropriate antimicrobials; or

The condition must be suspected or proven to be caused by gram-positive bacteria resistant to all other appropriate antimicrobials.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Epididymo-orchitis

The condition must be suspected or proven to be caused by gram-negative bacteria resistant to all other appropriate antimicrobials; or

The condition must be suspected or proven to be caused by gram-positive bacteria resistant to all other appropriate antimicrobials.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Prostatitis

The condition must be suspected or proven to be caused by gram-negative bacteria resistant to all other appropriate antimicrobials; or

The condition must be suspected or proven to be caused by gram-positive bacteria resistant to all other appropriate antimicrobials.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Perichondritis of the pinna

The condition must be suspected or proven to be caused by gram-negative bacteria resistant to all other appropriate antimicrobials; or

The condition must be suspected or proven to be caused by gram-positive bacteria resistant to all other appropriate antimicrobials.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Gonorrhoea

Sponsor: Alphapharm Pty Ltd ABN 93 002 359 739

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.